ライフサイエンスコーパス: delayed-type

1 tic ablation of NOX activity had reduced and delayed type 1 diabetes compared with NOD mice.

2 Systemic treatment of NOD mice significantly delayed type 1 diabetes onset.

3 ccination accelerated and CtfrII vaccination delayed type 1 diabetes.

4 bjects also exhibited a blunted and somewhat delayed type 1 T cell response to influenza vaccination,

5 erely impaired in IL-25(-/-) mice, including delayed type 2 cytokine responses, an attenuated functio

6 Delayed-type beta-lactam hypersensitivity develops in su

7 tact hypersensitivity (CHS) in the skin is a delayed type cellular immune response that can be mediat

8 suppression as measured by the inhibition of delayed type contact hypersensitivity to the chemical di

9 inflammation and hypersensitivity as well as delayed-type contact hypersensitivity were attenuated in

10 In contrast, delayed-type cutaneous hypersensitivity, a prototypic Th

11 ranscriptase inhibitor often inducing severe delayed-type drug hypersensitivity, can trigger innate i

12 model to study the pathologic role of HLA in delayed-type drug hypersensitivity.

13 Suppression of delayed type hypersensitivity (DTH) and in vivo lymphopr

14 tion correlates with a strong induction of a delayed type hypersensitivity (DTH) response following e

15 Maternal exposure to dLAN dampened delayed type hypersensitivity (DTH) responses in male of

16 IMP-1 and TIMP-2 had differential effects on delayed type hypersensitivity (DTH) responses to donor a

17 In this study, we show that cutaneous delayed type hypersensitivity (DTH) responses to recall

18 bined immunodeficiency mice to measure human delayed type hypersensitivity (DTH) responses.

19 T-cell (proliferation and delayed type hypersensitivity [DTH]) and B-cell (antibod

20 tivity, and cytokine production in vitro and delayed type hypersensitivity and inflammatory bowel dis

21 onor-specific regulation (DSR) by trans-vivo delayed type hypersensitivity assay at the time of enrol

22 rs before transplant and used the trans-vivo-delayed type hypersensitivity assay to measure immune re

23 The transvivo delayed type hypersensitivity assay was used to analyze

24 transplants as responders in the trans vivo-delayed type hypersensitivity assay, we found that dendr

25 Several models, including delayed type hypersensitivity in immune mice, and sponta

26 rotein showed potent in vivo efficacy in the delayed type hypersensitivity in rats.

27 f systemically activated T cells home to the delayed type hypersensitivity reaction induced by the ov

28 tenuated in subjects who are able to mount a delayed type hypersensitivity reaction to M. tuberculosi

29 s on ITK, which reduces an oxazolone-induced delayed type hypersensitivity reaction.

30 quisition of the capacity to mount cutaneous delayed type hypersensitivity reactions that disappeared

31 K14-mOVA Tg mice failed to mount T cell and delayed type hypersensitivity reactions to OVA, suggesti

32 global immunity as reflected by an enhanced delayed type hypersensitivity response and a 1.7-fold im

33 rechallenge prevented the development of the delayed type hypersensitivity response in vivo.

34 allogeneic tumor cells or the suppression of delayed type hypersensitivity responses against soluble

35 In addition, delayed type hypersensitivity responses are strongly imp

36 g/day) demonstrated significant decreases in delayed type hypersensitivity responses to tetanus, inte

37 Analysis by transvivo delayed type hypersensitivity showed that the reactivity

38 n a mucosal tolerization schedule suppressed delayed type hypersensitivity to E-selectin confirming t

39 proliferation of T(EM) cells and suppresses delayed type hypersensitivity when administered at 10 or

40 liferation of human TEM cells and suppresses delayed type hypersensitivity, a TEM cell-mediated react

41 me-linked immunosorbent assay, Western blot, delayed type hypersensitivity, and enzyme-linked immunos

42 In the mouse model of delayed type hypersensitivity, we have shown an essentia

43 autoreactive anti-MPO CD4(+) cells to induce delayed type hypersensitivity-like necrotizing glomerula

44 expression of the IL-2 receptor and promoted delayed type hypersensitivity.

45 gal and inhibited the ear-swelling assay for delayed type hypersensitivity.

46 antibodies and histopathologic, RT-PCR, and delayed-type hypersensitivity (DTH) analyses were used t

47 ompanied by vigorous cardiac myosin-specific delayed-type hypersensitivity (DTH) and antibody product

48 these mice developed cardiac myosin-specific delayed-type hypersensitivity (DTH) and autoantibodies i

49 st skin-infiltrating lymphocytes in allergic delayed-type hypersensitivity (DTH) and bacterial chancr

50 acy of JAK-3 inhibitors was determined using delayed-type hypersensitivity (DTH) and collagen-induced

51 e absence of injury, aged mice had depressed delayed-type hypersensitivity (DTH) and splenocyte proli

52 In 14 of 14 patients, delayed-type hypersensitivity (DTH) and/or CD4 prolifera

53 Delayed-type hypersensitivity (DTH) assays demonstrate t

54 , interleukin-2-induced pulmonary edema, and delayed-type hypersensitivity (DTH) in mice.

55 s mediate the suppression of donor-specific, delayed-type hypersensitivity (DTH) in tolerant organ tr

56 The effects of age, sex, and prevaccination delayed-type hypersensitivity (DTH) on the time course o

57 positive (responsive) or negative (anergic), delayed-type hypersensitivity (DTH) reaction to intrader

58 Safety, toxicity, delayed-type hypersensitivity (DTH) reaction, and induct

59 ntigen is injected, resulting in a classical delayed-type hypersensitivity (DTH) reaction.

60 All lesions were caused by allergic delayed-type hypersensitivity (DTH) reactions and not by

61 Delayed-type hypersensitivity (DTH) reactions elicited b

62 tory lymphokine essential for elicitation of delayed-type hypersensitivity (DTH) reactions in vivo.

63 the selectins play a role and predominate in delayed-type hypersensitivity (DTH) reactions of the ski

64 Systemic exposure to LTA or CPAF inhibited delayed-type hypersensitivity (DTH) reactions to the che

65 l inflammatory diseases including psoriasis, delayed-type hypersensitivity (DTH) reactions, and rheum

66 eumatoid arthritis, psoriasis, and cutaneous delayed-type hypersensitivity (DTH) reactions.

67 iphencyprone (DPCP) is a hapten that induces delayed-type hypersensitivity (DTH) reactions.

68 e and central memory subsets and inhibit the delayed-type hypersensitivity (DTH) response caused by s

69 o sand fly saliva in rodents induces a T(H)1 delayed-type hypersensitivity (DTH) response conferring

70 val, adverse events (AEs), and the effect of delayed-type hypersensitivity (DTH) response on clinical

71 There was a significant delayed-type hypersensitivity (DTH) response to adjuvant

72 /6 mice with indoles (I3C or DIM) attenuated delayed-type hypersensitivity (DTH) response to methylat

73 plex virus type 1 (HSV-1) develop a vigorous delayed-type hypersensitivity (DTH) response upon intrad

74 Delayed-type hypersensitivity (DTH) response was detecte

75 ized severe C. pneumoniae disease as being a delayed-type hypersensitivity (DTH) response with increa

76 antigen-specific proliferation in vitro, the delayed-type hypersensitivity (DTH) response, and serum

77 uppression in septic patients is an impaired delayed-type hypersensitivity (DTH) response, manifested

78 cterium bovis-specific antigens to stimulate delayed-type hypersensitivity (DTH) responses in cattle

79 n PPD were tested for the capacity to induce delayed-type hypersensitivity (DTH) responses in H37Rv-i

80 mmune cell infiltration at vaccine sites and delayed-type hypersensitivity (DTH) responses to autolog

81 Previously, we reported postvaccination delayed-type hypersensitivity (DTH) responses to autolog

82 The delayed-type hypersensitivity (DTH) responses to intrade

83 disease had high IgG antibody titers and no delayed-type hypersensitivity (DTH) responses to Leishma

84 mmunity, we hypothesized that decreased skin delayed-type hypersensitivity (DTH) responses to recall

85 to induce efferent T reg cells and suppress delayed-type hypersensitivity (DTH) responses.

86 ng, in vitro peptide recognition assays, and delayed-type hypersensitivity (DTH) responses.

87 ns ESAT-6, CFP-10, MPB70, and MPB83 elicited delayed-type hypersensitivity (DTH) skin test responses

88 otein antigen (TA90) expressed by PV, and by delayed-type hypersensitivity (DTH) skin testing with PV

89 Delayed-type hypersensitivity (DTH) testing in vivo and

90 egimen suppressed the strong myosin-specific delayed-type hypersensitivity (DTH) that normally develo

91 Patients were tested for delayed-type hypersensitivity (DTH) to autologous melano

92 polygyrus infection reduced the magnitude of delayed-type hypersensitivity (DTH) to PPD in the skin.

93 The challenged WT mice developed delayed-type hypersensitivity (DTH) to SEA; high levels

94 rfered with cell-mediated immunity as myosin delayed-type hypersensitivity (DTH) was reduced, while a

95 Hapten-evoked cutaneous delayed-type hypersensitivity (DTH) was significantly en

96 ssential mediators of autoimmune disease and delayed-type hypersensitivity (DTH), a convenient model

97 t survival, graft infiltration, allospecific delayed-type hypersensitivity (DTH), and cytokine expres

98 uble RAGE treatment is effective in reducing delayed-type hypersensitivity (DTH), even in RAGE(-/-) m

99 Delayed swelling reactions, i.e., delayed-type hypersensitivity (DTH), in response to an i

100 responsiveness by the ear-swelling test for delayed-type hypersensitivity (DTH), in vitro proliferat

101 Delayed-type hypersensitivity (DTH), suggesting T-cell r

102 This process resulted in a delayed-type hypersensitivity (DTH)-like EAE lesion.

103 were confirmed in vivo in a murine model of delayed-type hypersensitivity (DTH).

104 mals were unresponsive to PLP as measured by delayed-type hypersensitivity (DTH).

105 n and prevent the generation of allospecific delayed-type hypersensitivity (DTH).

106 ked the effects of UV in vivo and suppressed delayed-type hypersensitivity (DTH).

107 e differed from wild-type in the severity of delayed-type hypersensitivity (edema, T-cell and neutrop

108 velopment of specific antibody (P = .025) or delayed-type hypersensitivity (P = .03) responses to EGF

109 atic acid phosphatase (PAP) and a trans-vivo delayed-type hypersensitivity (tvDTH) assay, we found th

110 ic VL, (ii) asymptomatic infection (positive delayed-type hypersensitivity [DTH+]), or (iii) no evide

111 tein 60 was the only antigen shown to induce delayed-type hypersensitivity among other antigens teste

112 eactive T cells by ELISPOT and by trans-vivo delayed-type hypersensitivity analysis in a surrogate mu

113 Immunologic response was monitored by delayed-type hypersensitivity and [(3)H]thymidine prolif

114 HHE) associated with salutary or detrimental delayed-type hypersensitivity and AIDS phenotypes, respe

115 Myosin-specific delayed-type hypersensitivity and antibody production we

116 or in vivo inhibition, causing enhanced skin delayed-type hypersensitivity and antigen (Ag)-induced a

117 s several type 1 immune responses, including delayed-type hypersensitivity and autoimmunity in which

118 T cell responses and reduced inflammation in delayed-type hypersensitivity and clinical disease in EA

119 lammation and autoimmunity, murine models of delayed-type hypersensitivity and collagen-induced arthr

120 A in the a.c. displayed reduced OVA-specific delayed-type hypersensitivity and CTL responses, compare

121 ific mAb inhibited T cell-mediated models of delayed-type hypersensitivity and experimental autoimmun

122 Skin delayed-type hypersensitivity and experimental autoimmun

123 Furthermore, allospecific delayed-type hypersensitivity and gene expression of int

124 Delayed-type hypersensitivity and humoral immune respons

125 f AnxA1 also increased OVA-induced cutaneous delayed-type hypersensitivity and IFN-gamma and IL-17 re

126 lin epitope-specific Th1 effector functions (delayed-type hypersensitivity and IFN-gamma production)

127 ducing T lymphocyte-mediated inflammation in delayed-type hypersensitivity and in experimental autoim

128 Contact sensitivity (CS) is related to delayed-type hypersensitivity and is a well-characterize

129 reated mice, as indicated by reduced in vivo delayed-type hypersensitivity and reduced levels of sple

130 icking to draining lymph nodes, induction of delayed-type hypersensitivity and rejection of corneal t

131 age-related T cell dysfunction, Ag-specific delayed-type hypersensitivity and T cell proliferation w

132 n control IgG exhibited impaired Ag-specific delayed-type hypersensitivity and T cell proliferation,

133 e candidates due to their capacity to elicit delayed-type hypersensitivity and Th type 1-like cytokin

134 that excessive activity of T cells mediates delayed-type hypersensitivity and that cellular cytolysi

135 4 and CD8 effector responses in vivo, namely delayed-type hypersensitivity and tumor immunity.

136 Chlamydial delayed-type hypersensitivity antigens were analyzed by

137 tic capacity of uPA in the CIA model and the delayed-type hypersensitivity arthritis model.

138 reduced arthritis progression in the CIA and delayed-type hypersensitivity arthritis models.

139 Techniques, such as the trans vivo delayed-type hypersensitivity assay, ELISPOT and antigen

140 al blood of 45 patients using the trans-vivo delayed-type hypersensitivity assay.

141 MSCs was studied in vivo in a mouse model of delayed-type hypersensitivity assay.

142 from C57BL/6 CD4 KO mice were assessed using delayed-type hypersensitivity assays and Annexin V apopt

143 Delayed-type hypersensitivity assays demonstrated that i

144 Mixed-lymphocyte reactions and delayed-type hypersensitivity assays were performed to e

145 21 significantly enhanced the Th1-associated delayed-type hypersensitivity cutaneous responses.

146 HER2-specific delayed-type hypersensitivity developed in most patients

147 ection against disseminated candidiasis, but delayed-type hypersensitivity did.

148 immunopathology was found to be operative in delayed-type hypersensitivity footpad-swelling reaction

149 these cells to present Ag for elicitation of delayed-type hypersensitivity in previously immunized mi

150 of Th2 enhancement, as indicated by reduced delayed-type hypersensitivity in the context of enhanced

151 to inhibit T-cell proliferation and control delayed-type hypersensitivity in vivo.

152 press the keyhole limpet hemocyanin-specific delayed-type hypersensitivity inflammatory response.

153 sessment of Th1 function using the cutaneous delayed-type hypersensitivity model confirmed that p53(-

154 stopathological analysis of tissues from the delayed-type hypersensitivity model demonstrates that in

155 ed CD4(+) T-cell immune response in a murine delayed-type hypersensitivity model in vivo.

156 In a delayed-type hypersensitivity model, both T cell infiltr

157 able to reduce inflammation in a murine paw delayed-type hypersensitivity model, suppress the onset

158 ted anti-inflammatory properties in a murine delayed-type hypersensitivity model.

159 a T cells do not cause direct suppression of delayed-type hypersensitivity nor do they act as tolerog

160 hat disease is mediated by antigen-dependent delayed-type hypersensitivity or autoimmunity.

161 nodes (LNs) of mice with cOVA-induced airway delayed-type hypersensitivity reaction (DTHR) but not in

162 king RON exhibit increased inflammation in a delayed-type hypersensitivity reaction and increased sus

163 In a delayed-type hypersensitivity reaction in vivo, compound

164 A delayed-type hypersensitivity reaction test was administ

165 el of experimentally induced peritonitis and delayed-type hypersensitivity reaction.

166 easured from inhibition of ear swelling in a delayed-type hypersensitivity reaction.

167 However, severe delayed-type hypersensitivity reactions (DHR) induced by

168 d with E. chaffeensis, the animals developed delayed-type hypersensitivity reactions at cutaneous sit

169 naling of human T cells in vitro and reduces delayed-type hypersensitivity reactions in rats in vivo.

170 terolemia is frequent in these patients, and delayed-type hypersensitivity reactions in the arterial

171 TIGIT-Fc inhibited delayed-type hypersensitivity reactions in wild-type but

172 ve indicated that UVB-mediated inhibition of delayed-type hypersensitivity reactions is mediated, in

173 Posttreatment induction of delayed-type hypersensitivity reactions to autologous le

174 Patients have developed delayed-type hypersensitivity reactions to E75 postvacci

175 Immunization stimulated the development of delayed-type hypersensitivity reactions to irradiated, d

176 Immunization stimulated the development of delayed-type hypersensitivity reactions to irradiated, d

177 2) in the control of cutaneous inflammation, delayed-type hypersensitivity reactions were elicited in

178 e responses against intracellular pathogens, delayed-type hypersensitivity reactions, and induction o

179 d exhibited normal T cell priming and normal delayed-type hypersensitivity reactions.

180 ce compared with wild-type littermates after delayed-type hypersensitivity reactions.

181 han of PPD were needed to induce substantial delayed-type hypersensitivity reactions.

182 ine known to be essential for development of delayed-type hypersensitivity reactions.

183 cellular immune responses were determined by delayed-type hypersensitivity response and by a prolifer

184 showed that IL-27 regulated the severity of delayed-type hypersensitivity response and EAE through i

185 icance of the role of IL-27 was addressed in delayed-type hypersensitivity response and experimental

186 ignificantly stronger CD4(+) T-cell-mediated delayed-type hypersensitivity response and resulted in s

187 ry effect of alpha(1)beta(1) blockade on the delayed-type hypersensitivity response could be bypassed

188 owever, IL-10-deficient mice had an enhanced delayed-type hypersensitivity response during the chroni

189 ed allografts did not elicit an alloreactive delayed-type hypersensitivity response in graft recipien

190 VIP inhibited elicitation of a delayed-type hypersensitivity response in previously imm

191 fluence of photoperiod and acute stress on a delayed-type hypersensitivity response in the skin.

192 In a pattern-I-type delayed-type hypersensitivity response model, a similar

193 Inhibition of the delayed-type hypersensitivity response required that the

194 IL-10 transgenic mice demonstrated a smaller delayed-type hypersensitivity response to allogeneic cel

195 lymph nodes and allografts, 2) a suppressed delayed-type hypersensitivity response to B6D2F1 Ags, an

196 rative responses and a significantly reduced delayed-type hypersensitivity response to challenge anti

197 trates demonstrated a much weaker peripheral delayed-type hypersensitivity response to donor alloanti

198 et KO cells, gastritis was associated with a delayed-type hypersensitivity response to H. pylori anti

199 Lastly, P763.74, but not PGH786, induced a delayed-type hypersensitivity response to HMW-MAA-bearin

200 spleen T cells in vitro and inhibition of a delayed-type hypersensitivity response to oxazolone in v

201 on-induced immunosuppression, resulting in a delayed-type hypersensitivity response to photo-induced

202 -MEM mice responded with an enhanced footpad delayed-type hypersensitivity response, and more IFN-gam

203 lin E and inhibition of the anticryptococcal delayed-type hypersensitivity response, indicating a shi

204 nths), and recurrence correlated with a weak delayed-type hypersensitivity response.

205 condary infection, and exhibited an impaired delayed-type hypersensitivity response.

206 onsequently, these cells failed to sustain a delayed-type hypersensitivity response.

207 t not CpG 1826/IFA as an adjuvant elicited a delayed-type hypersensitivity response.

208 rdiac myosin (autoimmunity) but did decrease delayed-type hypersensitivity responses against both ant

209 , characterized by Ag-specific inhibition of delayed-type hypersensitivity responses and a reduction

210 n the periphery, which resulted in increased delayed-type hypersensitivity responses and autoimmune d

211 ACAID is characterized by decreases in delayed-type hypersensitivity responses and complement-f

212 Our data demonstrate that decorin modulates delayed-type hypersensitivity responses by augmenting th

213 induced Ag-specific T cell proliferation and delayed-type hypersensitivity responses in FcgammaRIIB-e

214 orphisms and haplotype pairs that influenced delayed-type hypersensitivity responses in healthy perso

215 reduced IFN-gamma production, and inhibited delayed-type hypersensitivity responses in immune mice c

216 ls, which failed to undergo proliferative or delayed-type hypersensitivity responses in recipients.

217 ma tumor cells, and tumor-loaded DC1s induce delayed-type hypersensitivity responses in vivo.

218 zation, because Jak3-/- chimeric mice showed delayed-type hypersensitivity responses indistinguishabl

219 administration of MSCs significantly reduced delayed-type hypersensitivity responses to allogeneic an

220 Delayed-type hypersensitivity responses to C57BL/6 alloa

221 ermined by the level of serum antibodies and delayed-type hypersensitivity responses to HMW-MAA-beari

222 yeloperoxidase CD4+ T cells, enhanced dermal delayed-type hypersensitivity responses to myeloperoxida

223 Liver but not spleen pDCs suppress delayed-type hypersensitivity responses to OVA, an effec

224 Furthermore, 139-iTregs inhibit delayed-type hypersensitivity responses to PLP139-151, b

225 n 42 patients with leprosy were compared for delayed-type hypersensitivity responses to purified prot

226 ount but was associated with higher rates of delayed-type hypersensitivity responses to TT (25% of su

227 of murine CD8(+) dendritic cells to suppress delayed-type hypersensitivity responses to tumor-associa

228 Baseline delayed-type hypersensitivity responses were enhanced du

229 41 vaccination decreased corneal opacity and delayed-type hypersensitivity responses while elevating

230 combinant murine IL-10 were able to suppress delayed-type hypersensitivity responses within injected

231 We used cutaneous delayed-type hypersensitivity responses, a powerful in v

232 Cs including enhanced T-cell reconstitution, delayed-type hypersensitivity responses, and class-switc

233 nterferon gamma-producing T cells, increased delayed-type hypersensitivity responses, and higher seru

234 es: rash, high fever, viremia, depression of delayed-type hypersensitivity responses, lowered leukocy

235 not age, was associated with impairments in delayed-type hypersensitivity responses, lymphoprolifera

236 ed bystander suppression of tetanus-specific delayed-type hypersensitivity responses, which was rever

237 rvival demonstrated prominent donor-reactive delayed-type hypersensitivity responses, which were incr

238 G(35-55) in vitro and demonstrated decreased delayed-type hypersensitivity responses.

239 They had significant leukopenia and reduced delayed-type hypersensitivity responses.

240 sitivity and enhancement of antigen-specific delayed-type hypersensitivity responses.

241 corin modulates leukocyte recruitment during delayed-type hypersensitivity responses.

242 cross-regulation of Th1 cells or exaggerated delayed-type hypersensitivity responses.

243 tor and memory T cells inhibited Ag-specific delayed-type hypersensitivity responses; similar decreas

244 ed antigen-specific T-cell proliferation and delayed-type hypersensitivity skin response.

245 Delayed-type hypersensitivity skin test responses were m

246 ral load, baseline CD4(+) T cell counts, and delayed-type hypersensitivity skin test responses, an in

247 assessed by in vitro proliferation assay and delayed-type hypersensitivity skin testing.

248 Delayed-type hypersensitivity skin tests showed that som

249 induced by IFN-gamma, TNF, TLR agonists, and delayed-type hypersensitivity than CCR4(-) cells.

250 hermore, ATPgammaS enhanced the induction of delayed-type hypersensitivity to a model tumor vaccine i

251 in the hosts and inhibited the expression of delayed-type hypersensitivity to donor alloantigens.

252 BALB/c mice with pre-established delayed-type hypersensitivity to hen OVA were immunized

253 of healthy subjects have tested positive for delayed-type hypersensitivity to soluble leishmania anti

254 ed immunologic memory and the elicitation of delayed-type hypersensitivity to the common opportunisti

255 filtrates responded strongly to donor Ags in delayed-type hypersensitivity trans-vivo assays.

256 vels of inflammation were seen in a model of delayed-type hypersensitivity using 2,4-dinitrofluoroben

257 Additionally, allospecific delayed-type hypersensitivity was compared among the gro

258 Delayed-type hypersensitivity was enhanced in women with

259 The correlations of increased delayed-type hypersensitivity with -2459G/G-containing C

260 nd gastric epithelial metaplasia), cellular (delayed-type hypersensitivity) and humoral immune respon

261 reactions triggered by immune (immediate and delayed-type hypersensitivity) and non-immune (intoleran

262 Sixteen subjects (out of 315 with CS delayed-type hypersensitivity) presented with allergic m

263 beta1AR(-/-) mice had improved cellular (delayed-type hypersensitivity) responses while beta2AR(-

264 nted a hallmark of sepsis (i.e., the loss of delayed-type hypersensitivity), which is an IFN-gamma- a

265 ction of antigen inhibits the development of delayed-type hypersensitivity, a phenomenon known as ant

266 mice exhibited T cell priming by peptide and delayed-type hypersensitivity, although these responses

267 , MAS, mean and cumulative arthritis scores, delayed-type hypersensitivity, and antibody responses to

268 , suppress primarily Th1 responses including delayed-type hypersensitivity, and transfer suppression

269 nies many type 1 immune responses, including delayed-type hypersensitivity, autoimmunity, and graft r

270 Delayed-type hypersensitivity, CD4 and CD8 counts, anti-

271 Immune responses were evaluated by delayed-type hypersensitivity, CD4+ T-cell proliferation

272 In a more generalized model of inflammation, delayed-type hypersensitivity, CP-481,715 significantly

273 respect to disease induction, enhancement of delayed-type hypersensitivity, enhancement of lymphocyte

274 clude mixed lymphocyte reactions, trans-vivo delayed-type hypersensitivity, enzyme-linked immunospot

275 es of T cell function--ranging from positive delayed-type hypersensitivity, in asymptomatic infected

276 ain aspects of immune function, particularly delayed-type hypersensitivity, may be improved in HD pat

277 Using Ag-specific delayed-type hypersensitivity, T cell proliferation, and

278 lls and prevented these mice from developing delayed-type hypersensitivity, which is critically depen

279 nate immune activation to medication-induced delayed-type hypersensitivity, which may stimulate new c

280 ogical exams and demonstration of leishmanin delayed-type hypersensitivity.

281 nodes and to the inflamed paw in a model of delayed-type hypersensitivity.

282 cytokines associated with the development of delayed-type hypersensitivity.

283 r apoptotic activity using a murine model of delayed-type hypersensitivity.

284 rized by impairment of Th1 responses such as delayed-type hypersensitivity.

285 on (IFN-gamma), nitric oxide production, and delayed-type hypersensitivity.

286 ion of Th1 splenocytes and increased in vivo delayed-type hypersensitivity.

287 ion of macrophage influx in a mouse model of delayed-type hypersensitivity.

288 hocytes, as well as an inability to manifest delayed-type hypersensitivity.

289 te-induced peritonitis and oxazolone-induced delayed-type hypersensitivity.

290 immediate-type hypersensitivity; and reduced delayed-type hypersensitivity.

291 immediate-type hypersensitivity and enhanced delayed-type hypersensitivity.

292 d induction of sepsis-induced suppression of delayed-type hypersensitivity.

293 of immunity by B. dendrobatidis, a modified delayed-type-hypersensitivity (DTH) protocol was develop

294 inished memory T-cell populations, decreased delayed-type-hypersensitivity responses and decreased in

295 It was effective in vivo at inhibiting the delayed type hypersensivity reaction in mice.

296 In addition, IRF-3-deficient BMDCs exhibited delayed type I IFN synthesis compared to control cells.

297 that robust virus replication accompanied by delayed type I interferon (IFN-I) signaling orchestrates

298 hypersensitivity (CHS) is a T cell-mediated delayed-type immune response which has been considered t

299 mechanism-mediated finding consistent with a delayed-type immune-mediated type IV hypersensitivity in

300 vity to corticosteroids is a common finding, delayed-type reactions being much more frequently encoun